{
  "guid": "gid://art19-episode-locator/V0/LdJ7x4m65FhooiGsTBrb-aCgbZJbHIZ-Z8I8RsAaUQc",
  "title": "The Race for a Vaccine",
  "description": "<p>Scientists are racing to make a vaccine for the coronavirus, collaborating across borders in what is usually a secretive and competitive field. But their cooperation has been complicated by national leaders trying to buy first claim on any breakthrough. Today, we explore how the fight to own a future coronavirus vaccine is revealing the boundaries of international solidarity.</p><p>Guest: <a href=\"https://www.nytimes.com/by/katrin-bennhold?smid=pc-thedaily\" target=\"_blank\">Katrin Bennhold</a>, Berlin bureau chief for The New York Times, spoke with Lidia Oostvogels, who researches infectious diseases with the German biotech company CureVac. For more information on today’s episode, visit nytimes.com/thedaily. </p><p>Background reading: </p><ul><li>The United States says it will share any vaccine breakthroughs with the world. So why did<a href=\"https://www.nytimes.com/2020/03/15/world/europe/cornonavirus-vaccine-us-germany.html?smid=pc-thedaily\" target=\"_blank\"> President Trump reportedly try to purchase</a> a German biotech company that is trying to develop a shot for the coronavirus?</li><li>The latest updates from<a href=\"https://www.nytimes.com/2020/04/01/world/coronavirus-news.html?smid=pc-thedaily\" target=\"_blank\"> top U.S. government scientists project</a> that the coronavirus could kill 100,000 to 240,000 Americans — even with strict social distancing.</li></ul>\n",
  "pubDate": "Wed, 1 Apr 2020 09:51:28 +0000",
  "author": "thedaily@nytimes.com (The New York Times)",
  "link": "https://www.nytimes.com/the-daily",
  "content:encoded": "<p>Scientists are racing to make a vaccine for the coronavirus, collaborating across borders in what is usually a secretive and competitive field. But their cooperation has been complicated by national leaders trying to buy first claim on any breakthrough. Today, we explore how the fight to own a future coronavirus vaccine is revealing the boundaries of international solidarity.</p><p>Guest: <a href=\"https://www.nytimes.com/by/katrin-bennhold?smid=pc-thedaily\" target=\"_blank\">Katrin Bennhold</a>, Berlin bureau chief for The New York Times, spoke with Lidia Oostvogels, who researches infectious diseases with the German biotech company CureVac. For more information on today’s episode, visit nytimes.com/thedaily. </p><p>Background reading: </p><ul><li>The United States says it will share any vaccine breakthroughs with the world. So why did<a href=\"https://www.nytimes.com/2020/03/15/world/europe/cornonavirus-vaccine-us-germany.html?smid=pc-thedaily\" target=\"_blank\"> President Trump reportedly try to purchase</a> a German biotech company that is trying to develop a shot for the coronavirus?</li><li>The latest updates from<a href=\"https://www.nytimes.com/2020/04/01/world/coronavirus-news.html?smid=pc-thedaily\" target=\"_blank\"> top U.S. government scientists project</a> that the coronavirus could kill 100,000 to 240,000 Americans — even with strict social distancing.</li></ul>\n",
  "enclosure": "",
  "itunes:title": "The Race for a Vaccine",
  "itunes:author": "The New York Times",
  "itunes:image": "",
  "itunes:duration": "00:24:33",
  "itunes:summary": "Scientists are racing to make a vaccine for the coronavirus, collaborating across borders in what is usually a secretive and competitive field. But their cooperation has been complicated by national leaders trying to buy first claim on any breakthrough. Today, we explore how the fight to own a future coronavirus vaccine is revealing the boundaries of international solidarity.\n\nGuest: Katrin Bennhold, Berlin bureau chief for The New York Times, spoke with Lidia Oostvogels, who researches infectious diseases with the German biotech company CureVac. For more information on today’s episode, visit nytimes.com/thedaily. \n\nBackground reading: The United States says it will share any vaccine breakthroughs with the world. So why did President Trump reportedly try to purchase a German biotech company that is trying to develop a shot for the coronavirus?The latest updates from top U.S. government scientists project that the coronavirus could kill 100,000 to 240,000 Americans — even with strict social distancing.",
  "itunes:subtitle": "Scientists are racing to make a vaccine for the coronavirus, collaborating across borders in what is usually a secretive and competitive field. But their cooperation has been complicated by national leaders trying to buy first claim on any breakthrough. Today, we explore how the fight to own a future coronavirus vaccine is revealing the boundaries of international solidarity.\n\nGuest: Katrin Bennhold, Berlin bureau chief for The New York Times, spoke with Lidia Oostvogels, who researches infectious diseases with the German biotech company CureVac. For more information on today’s episode, visit nytimes.com/thedaily. \n\nBackground reading: The United States says it will share any vaccine breakthroughs with the world. So why did President Trump reportedly try to purchase a German biotech company that is trying to develop a shot for the coronavirus?The latest updates from top U.S. government scientists project that the coronavirus could kill 100,000 to 240,000 Americans — even with strict social distancing.",
  "itunes:explicit": "no",
  "itunes:episodeType": "full"
}